What is the upside for catalyst Biosciences'stock?
4 Wall Street analysts have issued 1-year target prices for Catalyst Biosciences' shares. Their forecasts range from $4. 00 to $18. 00. On average, they expect Catalyst Biosciences' stock price to reach $13. 33 in the next twelve months. This suggests a possible upside of 2,283. 5% from the stock's current price.
Who holds catalyst Biosciences'stock?
Only 4.00% of the stock of Catalyst Biosciences is held by insiders. 60.27% of the stock of Catalyst Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for Catalyst Biosciences are expected to grow in the coming year, from ($2.86) to ($1.44) per share.
What are analysts'target prices for catalyst Biosciences'stock?
4 Wall Street analysts have issued 1-year target prices for Catalyst Biosciences' shares. Their forecasts range from $4.00 to $18.00. On average, they expect Catalyst Biosciences' stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 2,283.5% from the stock's current price.
When is catalyst Biosciences'next quarterly announcement?
Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022. View our earnings forecast for Catalyst Biosciences. How were Catalyst Biosciences' earnings last quarter?
When did Catalyst Biosciences go public?
April 07, 2017Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering. SOUTH SAN FRANCISCO, Calif. , April 07, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc.
Is Catalyst Biosciences a buy?
The 1 analysts offering 12-month price forecasts for Catalyst Biosciences Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +72.41% increase from the last price of 1.74.
Is CBIO a good investment?
The financial health and growth prospects of CBIO, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Should I buy or sell Catalyst Biosciences stock right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 2 hold ratings...
What is Catalyst Biosciences' stock price forecast for 2022?
4 equities research analysts have issued twelve-month target prices for Catalyst Biosciences' stock. Their forecasts range from $4.00 to $18.00. On...
How has Catalyst Biosciences' stock performed in 2022?
Catalyst Biosciences' stock was trading at $0.9140 at the beginning of 2022. Since then, CBIO stock has increased by 49.9% and is now trading at $1...
Are investors shorting Catalyst Biosciences?
Catalyst Biosciences saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 2,540,000 shares,...
When is Catalyst Biosciences' next earnings date?
Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Catalyst Biosciences' earnings last quarter?
Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.46) ear...
When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?
Shares of Catalyst Biosciences reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February...
Who are Catalyst Biosciences' key executives?
Catalyst Biosciences' management team includes the following people: Dr. Nassim Usman Ph.D. , Pres, CEO & Director (Age 62, Pay $613.11k) Ms. Se...
Who are some of Catalyst Biosciences' key competitors?
Some companies that are related to Catalyst Biosciences include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regener...
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ..
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to assist the Company in exploring strategic alternatives.
Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency
Investment company Kalos Management, Inc. (Current Portfolio) buys Vale SA, sells Consensus Cloud Solutions Inc, Intuitive Surgical Inc, Amarin Corp PLC, Catalyst Biosciences Inc, Paratek Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Kalos Management, Inc..
When will catalyst biosciences release its earnings?
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for CB 4332 for the treatment of Complement Factor I (CFI) deficiency (CFID).
How much does catalyst biosciences make?
Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Catalyst Biosciences.
What is the CBIO symbol?
How much money does Catalyst Biosciences make? Catalyst Biosciences has a market capitalization of $132.61 million and generates $20.95 million in revenue each year . The biopharmaceutical company earns $-56,240,000.00 in net income (profit) each year or ($2.93) on an earnings per share basis.
What is the P/E ratio of catalyst biosciences?
Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."
Is catalyst biosciences a buy?
The P/E ratio of Catalyst Biosciences is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is Marketbeat better than Catalyst Biosciences?
Catalyst Biosciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
When did the 1-15 reverse split happen?
What stocks does MarketBeat like better than Catalyst Biosciences? Wall Street analysts have given Catalyst Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains.